Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een studie van MACI bij patiënten van 10 tot 17 jaar met symptomatische chondrale of osteochondrale defecten van de knie (PEAK)

30 oktober 2026 bijgewerkt door: Vericel Corporation

Een prospectief, open-label, gerandomiseerd, gelijktijdig actief gecontroleerd, longitudinaal, multicenter, fase 3 klinisch onderzoek naar de veiligheid en werkzaamheid van MACI bij patiënten van 10 tot 17 jaar met symptomatische chondrale of osteochondrale defecten van de knie als gevolg van osteochondritis dissecans of acuut trauma

The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of participants aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.

Studie Overzicht

Gedetailleerde beschrijving

This is a 2-year prospective, multicenter, randomized, open-label, parallel group clinical trial; a total of 45 participants, ages 10 to 17 years, will be randomized to receive a 1-time treatment with MACI or microfracture (2:1, 30 MACI:15 microfracture).

After meeting screening criteria at the initial visit, all participants will have a screening arthroscopy to further assess study eligibility. During the screening arthroscopy, participants will be further evaluated against entry criteria. Cartilage lesion size will be measured prior to any cartilage repair procedure and randomization. All participants who meet the eligibility criteria and are considered suitable for treatment in the study will have a cartilage biopsy taken prior to randomization to study treatment. Eligible participants will be randomized during the screening arthroscopy procedure to receive either MACI or microfracture treatment. Participants randomized to microfracture will undergo the procedure during the screening arthroscopy.

All biopsied tissue will be sent to the Vericel manufacturing facility in Massachusetts, where the sample will be processed to isolate the autologous chondrocytes. Cells from participants randomized to the MACI group will be used in the preparation of the MACI implant; cells from participants randomized to the microfracture group will be cryopreserved.

Participants randomized to treatment with MACI will return within 12 weeks of the screening arthroscopy to undergo the chondrocyte implantation procedure via arthrotomy. Participants are to follow a recommended postoperative rehabilitation program and compliance with the rehabilitation schedule will be monitored.

Participants will be followed post-study treatment for 2 years (104 Weeks).

Studietype

Ingrijpend

Inschrijving (Geschat)

45

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • California
      • Palo Alto, California, Verenigde Staten, 94304
        • Werving
        • Stanford University School of Medicine
        • Contact:
        • Hoofdonderzoeker:
          • Kevin Shea
      • Sacramento, California, Verenigde Staten, 95817
        • Werving
        • Shriners Hospital for Children Northern California
        • Hoofdonderzoeker:
          • Brian Haus
        • Contact:
      • Sacramento, California, Verenigde Staten, 95817
        • Werving
        • University of California Davis Lawrence J. Ellison Ambulatory Care Center Orthopaedic Surgery
        • Hoofdonderzoeker:
          • Brian Haus
        • Contact:
    • Louisiana
      • New Orleans, Louisiana, Verenigde Staten, 70121
        • Werving
        • Ochsner Health System-Elmwood
        • Contact:
        • Hoofdonderzoeker:
          • Brian Godshaw
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21224
        • Werving
        • Johns Hopkins Hospital
        • Contact:
          • Rushyuan Jay Lee, MD
          • Telefoonnummer: 443-997-2663
          • E-mail: rlee74@jhmi.edu
        • Contact:
        • Hoofdonderzoeker:
          • Rushyuan Jay Lee
    • Michigan
      • Ann Arbor, Michigan, Verenigde Staten, 48106
        • Werving
        • University of Michigan Medsport Orthopaedic Surgery
        • Contact:
        • Hoofdonderzoeker:
          • Eileen Crawford
    • New York
      • The Bronx, New York, Verenigde Staten, 10467
        • Voltooid
        • Montefiore Medical Center/Albert Einstein College of Medicine
    • Ohio
      • Akron, Ohio, Verenigde Staten, 44308
        • Werving
        • Akron Children's Hospital
        • Contact:
        • Hoofdonderzoeker:
          • John Polousky
      • Columbus, Ohio, Verenigde Staten, 43202
        • Werving
        • The Ohio State University Jameson Crane Sports Medicine Institute
        • Contact:
        • Hoofdonderzoeker:
          • Christopher Kaeding
    • Pennsylvania
      • Philadelphia, Pennsylvania, Verenigde Staten, 19104
        • Werving
        • Penn Medicine University City
        • Contact:
        • Hoofdonderzoeker:
          • James Carey
      • Philadelphia, Pennsylvania, Verenigde Staten, 19104
        • Werving
        • The Children's Hospital of Philadelphia - The Hub for Clinical Collaboration
        • Contact:
        • Hoofdonderzoeker:
          • Theodore Ganley
    • Rhode Island
      • East Providence, Rhode Island, Verenigde Staten, 02914
        • Werving
        • University Orthopedics, Inc.
        • Contact:
        • Hoofdonderzoeker:
          • Nicholas Lemme
    • Texas
      • Houston, Texas, Verenigde Staten, 77094
        • Voltooid
        • Texas' Children Hospital
      • Plano, Texas, Verenigde Staten, 75024
        • Voltooid
        • Children's Medical Center Plano
    • Wisconsin
      • Milwaukee, Wisconsin, Verenigde Staten, 53201
        • Werving
        • Children's Hospital of Wisconsin
        • Contact:
        • Hoofdonderzoeker:
          • John Erickson

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

10 jaar tot 17 jaar (Kind)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Age 10 to 17 years at the time of planned randomization

  • Symptomatic cartilage or osteochondral defects

  • One or more International Cartilage Repair Society (ICRS) Grade III or IV chondral or unsalvageable osteochondral defects located on the femoral condyles and/or trochlea amenable to treatment with the surgical procedure determined at randomization (MACI or microfracture).

    1. Concurrent ICRS Grade I and II defects are acceptable on the tibia if they remain untreated (or are treated with debridement only) at the time of study treatment.
    2. Participants with a potentially re-attachable osteochondral fragment, identified by magnetic resonance imaging (MRI) and that has not previously been repaired, may be consented to the study and undergo baseline assessments per protocol and prior to confirmatory arthroscopy (Visit 2). At arthroscopy, an attempt will be made to reattach the osteochondral fragment. If this is successful, the participant will be excluded from the study and deemed an intra-operative screen failure. If the attempted reattachment fails and no other exclusion criteria apply, the participant may continue in the PEAK study: a MACI biopsy will be taken, the participant will be randomized and treated per protocol.
  • At least 1 defect size ≥1.5 cm2 on the patella, femoral condyles and/or the trochlea; defects include OCD lesions with a bone lesion depth of ≤6 mm and does not require a bone graft.

  • Salvageable OCD lesions must have failed prior conservative and a reparative treatment, and the participant still experiences pain associated with the osteochondral lesion. Participants with defects as a result of trauma or unknown etiology are eligible regardless of prior treatments.

  • Stable target knee (i.e., anterior and posterior cruciate ligaments should be free of laxity as well as stable and intact). Ligament repair or reconstruction procedures are allowed prior to screening arthroscopy.

  • Intact meniscus or partial meniscus (at least 50% of functional meniscus remaining) in the target knee. Meniscal repair or resection might be performed either staged or concurrent with the cartilage repair procedure provided that the surgeon was able to confirm that at least 50% of functional meniscus would remain after the corrective meniscal treatment.

  • Written informed consent

Exclusion Criteria:

  • Any surgery on the target knee joint within 6 months prior to Screening (not including diagnostic arthroscopy)

  • Previous investigational drug or device use within 3 months prior to Screening

  • Avascular necrosis of the target knee (other than potential OCD lesion to be treated)

  • Participants with uninvolved open growth plates where the surgery necessitates crossing the growth plate, or where the depth of the lesion crosses the growth plate

  • ICRS Grade III or IV chondral or unsalvageable osteochondral defects located on the tibia or any lesion that is bipolar to the index lesion

  • Malalignment requiring concurrent osteotomy to correct tibial-femoral or patella-femoral alignment (prior guided growth treatment is not exclusionary)

  • Symptomatic musculoskeletal conditions in the lower limbs that could impede measurement of efficacy for the target knee joint

  • Concomitant inflammatory disease or other conditions that affects the joints (eg, rheumatoid arthritis, metabolic bone disease, psoriasis, symptomatic chondrocalcinosis)

  • Known history of septic arthritis in the index knee joint

  • Current malignancy or treatment for malignancy within the past 5 years

  • Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin

  • Females who are pregnant or lactating

  • Participants who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Examples of significant problems included but are not limited to:

    • Any condition that has potential for negatively impacting intra or postoperative course
    • Conditions that limit compliance with rehabilitation program
    • Any condition that has potential for significantly limiting participant's ability to assess postoperative knee function
    • Any condition, psychiatric or otherwise, that would preclude informed consent/assent, consistent follow-up, or compliance with any aspect of the study
    • Participant is currently abusing drugs or alcohol or, in the opinion of the Investigator, at high risk for poor compliance

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: MACI

autologous cultured chondrocytes on porcine collagen membrane

autologous cultured chondrocytes on porcine collagen membrane

Ander: microfracture

surgical procedure

Arthroscopic microfracture treatment

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Proportion of Participants Who Achieve ≥ 10-point Improvement From Baseline in KOOS-Child Pain and Function (Sports and Recreational Activities) Subscale Scores
Tijdsspanne: Baseline and Week 104

A responder is defined as a participant with ≥ 10-point change (improvement) in both the KOOS-Child Pain and Function (Sports and Recreational activities) scores from Baseline scores. The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL).

Baseline and Week 104

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change from Baseline in KOOS-Child subscores
Tijdsspanne: Baseline and Week 104

The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL).

Baseline and Week 104
Change from Baseline in KOOS-Child subscores
Tijdsspanne: Baseline and Week 52

The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL).

Baseline and Week 52

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Treatment Emergent Adverse Events
Tijdsspanne: Week 104

A treatment emergent untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.

Week 104

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Jonathan Hopper, BSc (Hons), MB ChB, FRCSEd, Vericel Corporation

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

24 oktober 2018

Primaire voltooiing (Geschat)

1 februari 2030

Studie voltooiing (Geschat)

1 februari 2030

Studieregistratiedata

Eerst ingediend

4 april 2018

Eerst ingediend dat voldeed aan de QC-criteria

15 juli 2018

Eerst geplaatst (Werkelijk)

17 juli 2018

Updates van studierecords

Laatste update geplaatst (Werkelijk)

3 november 2026

Laatste update ingediend die voldeed aan QC-criteria

30 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren